ArticleVirchows Archiv : an international journal of pathology2026
Novel insights into immunohistochemical analysis of intrahepatic cholangiocarcinoma: ST6 N-acetylgalactosaminide alpha-2,6-sialyltransferase 1 (ST6GalNAc1) as a new marker for large duct type.
Article in Virchows Archiv : an international journal of pathology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Intrahepatic cholangiocarcinoma (iCCA) is histologically classified into the small duct type (SDT) and large duct type (LDT), although their morphological differential diagnosis can be difficult. We aimed to identify new immunohistochemical markers to classify SDT and LDT with high sensitivity and specificity. We compared the gene expression profiles of SDT and LDT using cases obtained from our institution (n = 8) and The Cancer Genome Atlas database (n = 28). We selected the candidate molecules that were up-regulated in LDT, were minimally or not expressed in SDT, and had specific and available antibodies suitable for immunohistochemistry. We finally selected ST6 N-acetylgalactosaminide alpha-2,6-sialyltransferase 1 (ST6GalNAc1), Breast carcinoma amplified sequence-1 (BCAS-1), and Olfactomedin 4 (OLFM4), which were expressed in 100%, 100%, and 98.3% of 58 LDT cases, respectively. ST6GalNAc1 was expressed in 3.8% of 52 SDT cases, whereas BCAS-1 and OLFM4 were expressed in 48.1% and 34.6% of SDT cases, respectively. ST6GalNAc1 was also expressed in intraductal papillary neoplasm of the bile duct (100%, n = 17) and only the adenocarcinoma component corresponding to LDT among the combined hepatocellular-cholangiocarcinoma cases (100%), but not in hepatocellular carcinoma (n = 26). In small biopsy specimens, ST6GalNAc1 was expressed in 100% of LDT (n = 18) and 12.5% of SDT (n = 16) samples. ST6GalNAc1 expression was associated with significantly shorter overall survival (P = 0.012) and remained significant after adjustment for tumor subtype (hazard ratio 2.595; 95% confidence interval, 1.433-4.699; P = 0.002). ST6GalNAc1 is useful for iCCA subtype identification with high sensitivity and specificity, showing promise to become a more powerful tool when combined with other markers.
Indexed as
Identifiers
42595919What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.